Saturday, July 11, 2026

pharma · Relapsing-Remitting Multiple Sclerosis · Spinal Muscular Atrophy

Biogen

Biogen is a pharma organization headquartered in VISAKHAPATNAM, IN. Primary therapeutic focus areas include Relapsing-Remitting Multiple Sclerosis, Spinal Muscular Atrophy, systemic lupus erythematosus, IgA nephropathy,

225 Binney Street, Cambridge, MA 02142, US HQ
7,534 Employees
NMPA registrant Type
Company details
Clinical program

Spinraza 12 mg solution for injection

Phase 1 · small molecule · Spinal Muscular Atrophy

Spinraza 12 mg solution for injection for Spinal Muscular Atrophy is a Phase 1 program (small_molecule) at Biogen with 1 ClinicalTrials.gov record(s).

← All Biogen projects Phase 1 small molecule active

Internal code 295SM101

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Biogen
Phase
Phase 1
Modality
small_molecule
Indication
Spinal Muscular Atrophy
Status
active
Trials
1